SQL 6.6 (+0%)
US81734C1062Medical Diagnostics & ResearchDiagnostics & Research

SeqLL (SQL) Competitor Comparison

We are evaluating the key criteria listed to compare SeqLL (SQL) against its competitors in the Diagnostics & Research industry.

Free Cashflow - SQL ranking 33 / 56

These are the competitors of SeqLL in the industry Diagnostics & Research ranked by free cashflow
1. Danaher DHR
5.2B
2. Thermo Fisher Scientific TMO
4.63B
3. Laboratory Corp of America Holdings LH
1.37B
4. IQVIA Holdings IQV
1.31B
5. Agilent Technologies A
816.37M
6. Mettler-Toledo MTD
661.92M
7. DexCom DXCM
596.21M
8. IDEXX Laboratories IDXX
586.36M
9. Icon ICLR
444.39M
10. Quest Diagnostics DGX
406.25M
11. Ortho Clinical Diagnostics Holdings OCDX
399.98M
12. Illumina ILMN
393.5M
13. Charles River Laboratories CRL
340.81M
14. Medpace Holdings MEDP
330.85M
15. Waters WAT
330.26M
16. Syneos Health SYNH
172.33M
17. Sotera Health SHC
116.55M
18. Neogen NEOG
76.91M
19. Qiagen QGEN
73.76M
20. RadNet RDNT
67.47M
21. Global Cord Blood CO
52.67M
22. Fulgent Genetics FLGT
27.04M
23. Inotiv NOTV
22.55M
24. CareDx CDNA
19.7M
25. National Research NRC
12.33M
26. Enzo Biochem ENZ
4.96M
27. Exact Sciences EXAS
2.55M
28. Interpace Biosciences IDXG
2.06M
29. Trinity Biotech TRIB
2.04M
30. Psychemedics PMD
907.38K
31. Precipio PRPO
-2.14M
32. Anixa Biosciences ANIX
-2.35M
33. SeqLL SQL
-2.72M
34. bioAffinity Technologies BIAF
-4.2M
35. Heska HSKA
-5.78M
36. Organovo Holdings ONVO
-9.84M
37. Co-Diagnostics CODX
-10.94M
38. DarioHealth DRIO
-11.72M
39. Aspira Womens Health AWH
-12.97M
40. NeoGenomics NEO
-13.1M
41. Sera Prognostics SERA
-14.61M
42. Myriad Genetics MYGN
-20.94M
43. Exagen XGN
-22.03M
44. MaxCyte MXCT
-22.26M
45. MDxHealth MDXH
-22.31M
46. Neuronetics STIM
-24.7M
47. Olink Holding OLK
-34.12M
48. Biodesix BDSX
-36.85M
49. Pacific Biosciences of California PACB
-49.26M
50. Personalis PSNL
-56.42M
51. Bioventus BVS
-83.78M
52. Twist Bioscience TWST
-114.6M
53. Guardant Health GH
-190.62M
54. Natera NTRA
-197.33M
55. PerkinElmer PKI
-262.12M
56. Lantheus Holdings LNTH
-269.94M

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.